Company News
Revolution Medicines Reports Positive Phase 3 Trial
Revolution Medicines shares jumped 33% after reporting positive Phase 3 RASolute 302 trial results in metastatic pancreatic cancer.
Daraxonrasib showed median overall survival of 13.2 months versus 6.
